Skip to Content

Join the 'Aptiom' group to help and get support from people like you.

Aptiom News

Sunovion’s Aptiom (eslicarbazepine acetate) Receives FDA Approval for Expanded Indication to Treat Partial-Onset Seizures in Children and Adolescents 4 Years of Age and Older

Posted 20 Sep 2017 by Drugs.com

MARLBOROUGH, Mass.--(BUSINESS WIRE)--September 14, 2017 Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) to expand the indication for its antiepileptic drug (AED) Aptiom (eslicarbazepine acetate) to include treatment of partial-onset seizures (POS) in children and adolescents four to 17 ...

Pot Compound Alters Levels of Seizure Drug in Epilepsy Patients

Posted 11 Aug 2017 by Drugs.com

FRIDAY, Aug. 11, 2017 – Scientists experimenting with the marijuana compound cannabidiol as an epilepsy treatment must evaluate any interactions with other anti-seizure drugs patients are taking, researchers report. The new research from the University of Alabama at Birmingham suggests cannabidiol affects blood levels of several anti-seizure drugs, especially clobazam. Cannabidiol (CBD) has ...

One-a-Day Anti-Seizure Drug Shows Promise for People With Epilepsy

Posted 15 Apr 2016 by Drugs.com

THURSDAY, April 14, 2016 – A once-daily epilepsy drug may control seizures just as well as a twice-daily drug, researchers report. Their preliminary study compared the once-a-day drug eslicarbazepine acetate (Aptiom) to the twice-daily drug carbamazepine (Tegretol, Carbatrol) for more than 800 people newly diagnosed with partial seizures, which originate in one area of the brain. After six ...

FDA Approves New Indication for Aptiom (eslicarbazepine acetate) as Monotherapy for Partial-Onset Seizures

Posted 31 Aug 2015 by Drugs.com

Marlborough, Mass., August 28, 2015 – Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Aptiom (eslicarbazepine acetate) as monotherapy for the treatment of partial-onset seizures. This new approved indication allows Aptiom to be used as monotherapy in people who initiate treatment f ...

Ask a Question

Further Information

Related Condition Support Groups

Seizures

Aptiom Patient Information at Drugs.com